[Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease].
暂无分享,去创建一个
L. Mendeleeva | I. Galtseva | V. Savchenko | L. Kuzmina | N. Kapranov | M. Nareyko | M. Firsova | E. Gemdzhian | Y. Davydova | M. Solovyev | O. S. Pokrovskaya
[1] L. Mendeleeva,et al. Maintenance Therapy after Autologous Haematopoietic Stem Cell Transplantation (auto-HSCT) in Multiple Myeloma Patients with and without Minimal Residual Disease (MRD) , 2016 .
[2] S. Rajkumar,et al. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[3] A. Órfão,et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition , 2016, Cytometry. Part B, Clinical cytometry.
[4] D. Dingli,et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] U. Mellqvist,et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. , 2013, Blood.
[6] A. Oriol,et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. , 2012, Blood.
[7] M. Kersten,et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] B. Pégourié,et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.
[9] D. Esseltine,et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. , 2010, Blood.
[10] S. Lonial,et al. The Importance of Complete Response in Outcomes in Myeloma , 2009, Cancer Journal.
[11] L. Escoda,et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Órfão,et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. , 2008, Blood.
[13] P. Richardson,et al. Clinically relevant end points and new drug approvals for myeloma , 2008, Leukemia.
[14] Jason McCoy,et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Ravaud,et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Bataille,et al. Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.
[17] M. Dimopoulos,et al. Randomized trial of α‐interferon or dexamethasone as maintenance treatment for multiple myeloma , 2000 .
[18] M. Gore,et al. A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results , 1998, British journal of haematology.
[19] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .